USD 0.42
(-15.14%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 10.01 Million USD | 285.79% |
2022 | 2.59 Million USD | -98.88% |
2021 | 231.76 Million USD | 12414.54% |
2020 | 1.85 Million USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 6.43 Million USD | -13.15% |
2024 Q1 | 7.4 Million USD | -26.09% |
2023 Q4 | 10.01 Million USD | -46.1% |
2023 FY | 10.01 Million USD | 285.79% |
2023 Q3 | 18.58 Million USD | -57.77% |
2023 Q2 | 44 Million USD | 1.93% |
2023 Q1 | 43.17 Million USD | 0.75% |
2022 Q1 | 231.23 Million USD | -0.23% |
2022 FY | 2.59 Million USD | -98.88% |
2022 Q4 | 42.85 Million USD | 1.65% |
2022 Q3 | 42.15 Million USD | -81.75% |
2022 Q2 | 231.02 Million USD | -0.09% |
2021 Q3 | 232 Million USD | 0.0% |
2021 FY | 231.76 Million USD | 12414.54% |
2021 Q4 | 231.76 Million USD | -0.1% |
2020 FY | 1.85 Million USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AIM ImmunoTech Inc. | 19.38 Million USD | 48.305% |
Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -74.669% |
Armata Pharmaceuticals, Inc. | 109.96 Million USD | 90.889% |
Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 87.698% |
Azitra, Inc. | 5.11 Million USD | -95.856% |
Can-Fite BioPharma Ltd. | 9.98 Million USD | -0.3% |
Chromocell Therapeutics Corporation | 96.39 Thousand USD | -10294.124% |
CEL-SCI Corporation | 30.52 Million USD | 67.181% |
iBio, Inc. | 28.73 Million USD | 65.132% |
Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 90.082% |
MAIA Biotechnology, Inc. | 7.56 Million USD | -32.406% |
Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 84.722% |
Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -129.184% |
NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -10.903% |
NanoViricides, Inc. | 12.82 Million USD | 21.866% |
Oragenics, Inc. | 4.96 Million USD | -101.738% |
BiomX Inc. | 58.15 Million USD | 82.772% |
BiomX Inc. | 58.15 Million USD | 82.772% |
Protalix BioTherapeutics, Inc. | 84.43 Million USD | 88.134% |
Palatin Technologies, Inc. | 10.74 Million USD | 6.733% |
Scorpius Holdings, Inc. | 51.03 Million USD | 80.369% |
Theriva Biologics, Inc. | 60.21 Million USD | 83.36% |